secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001493152-23-031526
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences enters $10M ATM equity distribution agreement with Canaccord Genuity
--------------------------------------------------------------------------------

- Initial offering limited to $2,392,514 due to public float restrictions under Form S-3 as of September 1, 2023.
- Canaccord receives 3.0% commission on gross sales; Company to reimburse certain expenses.
- Net proceeds for general corporate purposes: R&D, working capital, debt reduction, acquisitions.
- Shares sold under existing effective shelf registration statement (File No. 333-257690).
- Agreement includes customary representations, warranties, and indemnification provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/0001493152-23-031526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223031526/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-031526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer